Abstract
Supplementary figure S4 shows the Tumor infiltrating immune cell profiling in MC38 co-implantation model (A) Schematic of the in vivo co-implantation and FACS study design with or without AEBP1 co-implantation. (B) Mean tumor volumes measured at time of sample collection for FACS. (C) FACS gating strategy for assessment of TILs (D) Quantification of immune infiltrates in MC38 tumor alone and MC38 tumors co-implanted with AEBP1 WT fibroblasts or AEBP1 KO fibroblasts.